● Recruiting

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

Condition: Post-COVID / Long-COVID · Sponsor: Nancy Klimas

PhasePhase 2

Planned participants100

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

This description comes directly from the study's public registry record.

Talk to the study team

Nancy Klimas, MD · 954-262-2286 · nklimas@nova.edu

Alejandro Montealegre, MSN, ARNP · 954-262-2286 · am3841@nova.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Nova Southeastern University

Fort Lauderdale, Florida, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07021794